Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL B22GK 4 2 5 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL B22GK 4 2 5 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 2 5 IN PLASTIC CONTAINER.
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER vs PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prismasol B22GK 4/2.5 is a hemofiltration solution used for continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct metabolic acidosis and maintains electrolyte balance while removing waste products via convective and diffusive clearance.
Prismasol BGK 4/2.5 is a hemofiltration solution used in continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct metabolic acidosis and maintain acid-base and electrolyte balance during hemofiltration. The solution contains lactate as a buffer, which is metabolized to bicarbonate in the liver, helping to replace lost bicarbonate and correct metabolic acidosis.
Continuous renal replacement therapy (CRRT) solution; dosing based on prescribed effluent rate, typically 20-35 mL/kg/h. Route: intravenous via CRRT circuit.
Continuous renal replacement therapy (CRRT) solution; dose is operator-dependent based on prescribed effluent rate (typically 20-35 mL/kg/h) and patient metabolic needs. Not intended for direct intravenous infusion as a standalone drug.
None Documented
None Documented
Not applicable as a dialysis solution. Individual components have varying half-lives: glucose ~1.5-2 h, lactate ~0.5-1.5 h, electrolytes depend on renal function.
The components of PRISMASOL BGK 4/2.5 have elimination half-lives that depend on dialysis settings. For electrolytes, the serum half-life following a single dose is approximately 1-2 hours during continuous renal replacement therapy (CRRT) due to continuous removal. Without dialysis, the half-life of potassium is 7-10 hours in renal impairment, but the solution is only used during CRRT, so the effective half-life is governed by dialysis clearance.
PRISMASOL B22GK 4/2.5 is a hemodialysis solution; its components are primarily removed via dialysis. Electrolytes and lactate are eliminated renally in patients with residual function, but in ESRD, clearance is via dialysis. Glucose is metabolized or removed by dialysis.
PRISMASOL BGK 4/2.5 is a hemodialysis solution containing electrolytes (sodium, potassium, calcium, magnesium, chloride) and glucose. Its components are not metabolized; electrolytes are excreted renally in proportion to renal function, and glucose is either utilized or excreted renally if hyperglycemic. In continuous renal replacement therapy, the solution is removed via the dialysate/effluent (100% removal by dialysis). Renal excretion of electrolytes and glucose accounts for <5% in anuric patients, but in patients with residual renal function, up to 10-20% may be excreted renally. Overall, >95% is removed by the dialysis circuit.
Category C
Category C
Dialysis Solution
Dialysis Solution